FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2067320629> ?p ?o ?g. }

• W2067320629 endingPage "1368" @default.
• W2067320629 startingPage "1363" @default.
• W2067320629 abstract "We treated patients under age 50 years with iodine-131 (131I)–anti-CD45 antibody combined with fludarabine and 2 Gy total body irradiation to create an improved hematopoietic cell transplantation (HCT) strategy for advanced acute myeloid leukemia or high-risk myelodysplastic syndrome patients. Fifteen patients received 332 to 1561 mCi of 131I, delivering an average of 27 Gy to bone marrow, 84 Gy to spleen, and 21 Gy to liver. Although a maximum dose of 28 Gy was delivered to the liver, no dose-limiting toxicity was observed. Marrow doses were arbitrarily capped at 43 Gy to avoid radiation-induced stromal damage; however, no graft failure or evidence of stromal damage was observed. Twelve patients (80%) developed grade II graft-versus-host disease (GVHD), 1 patient developed grade III GVHD, and no patients developed grade IV GVHD during the first 100 days after HCT. Of the 12 patients with chronic GVHD data, 10 developed chronic GVHD, generally involving the skin and mouth. Six patients (40%) are surviving after a median of 5.0 years (range, 4.2 to 8.3 years). The estimated survival at 1 year was 73% among the 15 treated patients. Eight patients relapsed, 7 of whom subsequently died. The median time to relapse among these 8 patients was 54 days (range, 26 to 1364 days). No cases of nonrelapse mortality were observed in the first year after transplantation. However, 2 patients died in remission from complications of chronic GVHD and cardiomyopathy, at 18 months and 14 months after transplantation, respectively. This study suggests that patients may tolerate myeloablative doses >28 Gy delivered to the liver using 131I-anti-CD45 antibody in addition to standard reduced-intensity conditioning. Moreover, the arbitrary limit of 43 Gy to the marrow may be unnecessarily conservative, and continued escalation of targeted radioimmunotherapy doses may be feasible to further reduce relapse." @default.
• W2067320629 created "2016-06-24" @default.
• W2067320629 creator A5004025497 @default.
• W2067320629 creator A5004610095 @default.
• W2067320629 creator A5007024434 @default.
• W2067320629 creator A5011099910 @default.
• W2067320629 creator A5016684714 @default.
• W2067320629 creator A5023949296 @default.
• W2067320629 creator A5040412322 @default.
• W2067320629 creator A5050374901 @default.
• W2067320629 creator A5056405520 @default.
• W2067320629 creator A5062275451 @default.
• W2067320629 creator A5076899086 @default.
• W2067320629 creator A5078791373 @default.
• W2067320629 creator A5084915025 @default.
• W2067320629 creator A5085787488 @default.
• W2067320629 creator A5090982367 @default.
• W2067320629 date "2014-09-01" @default.
• W2067320629 modified "2023-10-16" @default.
• W2067320629 title "Radiolabeled Anti-CD45 Antibody with Reduced-Intensity Conditioning and Allogeneic Transplantation for Younger Patients with Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome" @default.
• W2067320629 cites W1492609361 @default.
• W2067320629 cites W1576593419 @default.
• W2067320629 cites W1954992673 @default.
• W2067320629 cites W1965699746 @default.
• W2067320629 cites W1973018895 @default.
• W2067320629 cites W1977384601 @default.
• W2067320629 cites W1978659582 @default.
• W2067320629 cites W1980996503 @default.
• W2067320629 cites W1994780830 @default.
• W2067320629 cites W1994795175 @default.
• W2067320629 cites W2018248363 @default.
• W2067320629 cites W2032451420 @default.
• W2067320629 cites W2048623536 @default.
• W2067320629 cites W2079644267 @default.
• W2067320629 cites W2117550229 @default.
• W2067320629 cites W2128812336 @default.
• W2067320629 cites W2129834424 @default.
• W2067320629 cites W2133882794 @default.
• W2067320629 cites W2148278841 @default.
• W2067320629 cites W2157202189 @default.
• W2067320629 cites W2169733452 @default.
• W2067320629 cites W2269690597 @default.
• W2067320629 cites W2273204150 @default.
• W2067320629 cites W2327658873 @default.
• W2067320629 cites W2330413599 @default.
• W2067320629 cites W2415998525 @default.
• W2067320629 cites W4244166141 @default.
• W2067320629 cites W71007469 @default.
• W2067320629 doi "https://doi.org/10.1016/j.bbmt.2014.05.014" @default.
• W2067320629 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4127337" @default.
• W2067320629 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24858425" @default.
• W2067320629 hasPublicationYear "2014" @default.
• W2067320629 type Work @default.
• W2067320629 sameAs 2067320629 @default.
• W2067320629 citedByCount "50" @default.
• W2067320629 countsByYear W20673206292015 @default.
• W2067320629 countsByYear W20673206292016 @default.
• W2067320629 countsByYear W20673206292017 @default.
• W2067320629 countsByYear W20673206292018 @default.
• W2067320629 countsByYear W20673206292019 @default.
• W2067320629 countsByYear W20673206292020 @default.
• W2067320629 countsByYear W20673206292021 @default.
• W2067320629 countsByYear W20673206292022 @default.
• W2067320629 countsByYear W20673206292023 @default.
• W2067320629 crossrefType "journal-article" @default.
• W2067320629 hasAuthorship W2067320629A5004025497 @default.
• W2067320629 hasAuthorship W2067320629A5004610095 @default.
• W2067320629 hasAuthorship W2067320629A5007024434 @default.
• W2067320629 hasAuthorship W2067320629A5011099910 @default.
• W2067320629 hasAuthorship W2067320629A5016684714 @default.
• W2067320629 hasAuthorship W2067320629A5023949296 @default.
• W2067320629 hasAuthorship W2067320629A5040412322 @default.
• W2067320629 hasAuthorship W2067320629A5050374901 @default.
• W2067320629 hasAuthorship W2067320629A5056405520 @default.
• W2067320629 hasAuthorship W2067320629A5062275451 @default.
• W2067320629 hasAuthorship W2067320629A5076899086 @default.
• W2067320629 hasAuthorship W2067320629A5078791373 @default.
• W2067320629 hasAuthorship W2067320629A5084915025 @default.
• W2067320629 hasAuthorship W2067320629A5085787488 @default.
• W2067320629 hasAuthorship W2067320629A5090982367 @default.
• W2067320629 hasBestOaLocation W20673206291 @default.
• W2067320629 hasConcept C126322002 @default.
• W2067320629 hasConcept C141071460 @default.
• W2067320629 hasConcept C2776694085 @default.
• W2067320629 hasConcept C2776755627 @default.
• W2067320629 hasConcept C2778461978 @default.
• W2067320629 hasConcept C2778729363 @default.
• W2067320629 hasConcept C2778880498 @default.
• W2067320629 hasConcept C2779263901 @default.
• W2067320629 hasConcept C2779282312 @default.
• W2067320629 hasConcept C2780007613 @default.
• W2067320629 hasConcept C2780817109 @default.
• W2067320629 hasConcept C2911091166 @default.
• W2067320629 hasConcept C71924100 @default.
• W2067320629 hasConcept C90924648 @default.
• W2067320629 hasConceptScore W2067320629C126322002 @default.
• W2067320629 hasConceptScore W2067320629C141071460 @default.
• W2067320629 hasConceptScore W2067320629C2776694085 @default.

• next